MAVACAMTEN (Camzyos®)

Clinical Indication

For treating symptomatic obstructive hypertrophic cardiomyopathy.

Comments

As per NICE TA913

Date of classification

December 2023

Red

Medicines which should be prescribed only in a specialist setting usually within a secondary or tertiary care service. NB: Some highly specialised RED medicines e.g. injectable treatments for cancer are not included on the LLR APC website list.